Decisions about add-on reimbursement for medical devices in France in June 2020

06

Jul 2020

The French National Authority for Health (HAS) released new decisions about add-on and medical aid reimbursement of many medical devices from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in June 2020.

The first step in the assessment is the clinical benefit, which can be either sufficient or insufficient. This step determines the insertion into the LPPR list. If sufficient, the clinical added value is graded on a scale from I (major) to V (absent), which supports the pricing decisions.

No decisions were released for cardiovascular devices.

Six (6) decisions were released for orthopaedic devices:

  • PRODISC O, total lumbar disc prosthesis (registration for renewal; insufficient clinical benefit)
  • OSTEOPURE, viro-inactivated bone allograft (application for modification of registration conditions and renewal of registration; sufficient clinical benefit; level V clinical added value compared to other virally inactivated bone allografts)
  • PRODISC L, total lumbar disc prosthesis (application for renewal; sufficient clinical benefit; level V clinical added value)
  • MOBIDISC, total lumbar disc prosthesis (application for renewal; sufficient clinical benefit; level V clinical added value compared to arthrodesis). Soon after, the request was canceled by the manufacturer
  • MEDPOR CRANIAL HEMISPHERE, standard anatomically shaped bone substitute for cranial reconstruction (application for registration; sufficient clinical benefit; level V clinical added value compared to similar already registered items)
  • AIR +, arthroscopic meniscal repair system (application for registration; sufficient clinical benefit; level V clinical added value compared to other meniscal repair devices)

Four (4) decisions were released for other devices:

  • DOMUS 4 AUTO, alternating pressure motorized air mattress with associated compressor (application for modification of registration conditions; sufficient clinical benefit; level V clinical added value compared to similar mattresses)
  • XPRESS, sinus dilation balloon device (application for registration; sufficient clinical benefit; level V clinical added value compared to functional endoscopic sinus surgery)
  • ASPIRESR, left vagus nerve stimulation system (application for modification of registration conditions and renewal of registration; sufficient clinical benefit; level V clinical added value compared to DEMIPULSE generators (models 103 and 104))
  • IALUSET, cream and impregnated compress (application for renewal; sufficient clinical benefit; level V clinical added value compared to DUODERM E hydrocolloid dressing)

See the latest decisions in French here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

18

Mar 2022

On February 22, 2022, a repository of innovative acts outside the nomenclature of biology and anatomopathology (RIHN) and a Supplementary list of IVD tests were published. Minor changes were introduced in the 2022 RIHN list.

Read more

14

Mar 2022

In February 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, published Bulletins 0182 and 0079 with changes to be implemented no later than April 10, 2022. Three new procedure codes concerned robotic surgery in orthopaedic area, spinal procedures, and ophthalmology, and five new diagnostic codes were introduced.

Read more

08

Mar 2022

At the end of February 2022, the Dental and Pharmaceutical Benefits Agency (TLV) has launched a theme survey on products for monitoring and diagnostics of sepsis to identify products that may be relevant for health economic assessments at TLV. The suggestions for the products of interest, ongoing clinical studies, or innovation projects could be received until 23 March 2022.

Read more

07

Mar 2022

On February 08, 2022, the Reimbursement Commission of the Social Security Institution released an updated version of the Healthcare Implementation Communique. The main changes relate to the increase in reimbursement fees of services and medical devices by approximately 35-75%.

Read more

03

Mar 2022

In February 2022, two more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, thirty health apps are now available at the DiGA Directory.

Read more